Taysha Gene Therapies Reports Zero Revenue and Increased Losses in Q2 2026

Taysha Gene Therapies, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded no revenue during the quarter, a decrease from $1.986 million in the same period last year. For the first half of 2026, Taysha's revenue remained at zero, compared to $4.288 million for the first half of 2025, which was derived from research and development activities related to its collaboration with Astellas Gene Therapies. The absence of revenue reflects the company's ongoing focus on clinical trials rather than product sales.

Operating expenses for the second quarter of 2026 totaled $47.349 million, up from $28.739 million in the prior year, driven primarily by increased research and development costs associated with the ongoing clinical trials for its lead product candidate, TSHA-102. Research and development expenses surged to $38.636 million from $20.141 million year-over-year, reflecting heightened activity in the BLA-enabling manufacturing initiatives and clinical trials. General and administrative expenses also rose to $12.146 million from $8.598 million, attributed to higher compensation and professional fees.

The company reported a net loss of $46.639 million for the second quarter of 2026, compared to a net loss of $26.882 million in the same quarter of 2025. For the first half of 2026, the net loss was $89.049 million, significantly higher than the $48.411 million loss reported in the first half of 2025. The increase in losses is primarily due to the ramp-up of clinical trial activities and associated costs.

In terms of operational developments, Taysha has made strategic moves, including the termination of its lease for a manufacturing facility in North Carolina, which resulted in a net gain of $3.433 million recognized in the financial statements. The company also successfully completed an underwritten public offering in June 2026, raising approximately $215.6 million, which is expected to support its ongoing clinical development and operational needs. As of June 30, 2026, Taysha had cash and cash equivalents of $455.4 million, which management believes will fund operations for at least the next twelve months.

Looking ahead, Taysha Gene Therapies anticipates continued significant operating losses as it invests in the development of TSHA-102 for Rett syndrome and other potential product candidates. The company is focused on advancing its clinical trials and preparing for regulatory submissions, with expectations of further capital requirements to support these initiatives. The management remains optimistic about the potential for future revenue generation upon successful product development and regulatory approval.